Evaluation of the quality of life in patients with multiple sclerosis

Authors

DOI:

https://doi.org/10.22141/2224-0713.16.6.2020.215141

Keywords:

multiple sclerosis, quality of life, disability, depression, anxiety, stress

Abstract

Multiple sclerosis (MS) is the best known and widespread demyelinating disease of the nervous system. About 3 million people suffer from MS in the world (about 0.5–1 ‰) and about 20,000 in Ukraine. It is among the “four horsemen of the neurological apocalypse” due to its medical and social implications. The disease ranks second among the disabled patients of working age and is accompanied by the acute neuropsychological changes, which manifest themselves in the abnormal behavior. The use of drugs of pathogenetic and symptomatic therapy, including the remedies that slow the progression of the disease, allows increasing the life expectancy of most patients with MS. However, there are several non-motor factors that change during the course of the disease, modifying the patient’s self-perception, professional, and social qualities. Such people are often prone to depression and anxiety, they are emotionally unstable and prone to frequent and sudden mood swings. An integral indicator of the physical, psychological, emotional, and social functioning of a patient with MS is the quality of life. The research provides an evaluation of the quality of life in MS patients with disability.

References

Ulitsky L.A., Chukhlovina M.L. Diagnosis of nervous diseases. 2001. P. 372.

Chuprina G.M. Multiple sclerosis: etiology, pathogenesis, clinic, diagnostics, differential diagnosis, treatment (clinical lecture). Eastern European Neurological Journal. 2017. 5. P. 27-37.

Sokolova L.I. Multiple sclerosis: key signs and treatments. III International Conference: Advances in Neurology. April 11–13, 2019.

Sharov D.A. Integral assessment of quality of life of patients with multiple sclerosis. Neuroimmunology. 2009. 1. P. 105-106.

Schwartz C.E., Foley F.W., Rao S.M., Bernardin L.J., Lee H., Genderson M.W. Stress and Course of Disease in Multiple Sclerosis. Behavioral Medicine. 1999. 25. 3. P. 110-116. doi: 10.1080/08964289909596740.

Janardhan V., Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. Journal of the neurological sciences. 2002. 205 (1). P. 51-58.

Beiske A.G., Svensson E., Sandanger I., Czujko B., Pedersen E.D., Aarseth J.H., Myhr K.M. Depression and Anxiety amongst Multiple Sclerosis Patients. European Journal of Neurology. 2008. 15. P. 239-245. doi: 10.1111/j.1468-1331.2007.02041.x.

Masaaki Niino, Yusei Miyazaki. Cognitive impairment as one of the important nonmotor symptoms in multiple sclerosis and neuromyelitis optica spectrum disorders. Clinical and Experimental Neuroimmunology. 2019. Vol. 10, Issue 3. doi: 10.1111/cen3.12528.

Beiske A.G. Non-motor symptoms in multiple sclerosis. Doctoral thesis, University of Oslo, 2009.

Gusev E.I., Boyko A.N. Multiple sclerosis: achievements of the decade. Journal of Neurology and Psychiatry. 2007. 4. P. 4-14.

Schmidt T.E. Pathogenetic treatment of multiple sclerosis. Medical Council. 2010. 9–10. P. 74-79.

Downloads

Published

2020-09-01

Issue

Section

Original Researches